文献速递炎症性肠病

维多珠单抗在老年与非老年炎症性肠病患者匹配队列中的有效性与安全性:IG-IBD LIVE研究

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-05-12

LIVE研究为回顾-前瞻性研究,纳入2016年4月至2017年6月起始维多珠单抗的溃疡性结肠炎(UC)和克罗恩病(CD)患者,老年(≥65岁)按1:2匹配非老年(18-64岁),随访至停药或2019年6月。老年UC患者持续用药率显著低于非老年(51.4% vs 67.6%,p=0.02),CD组疗效无显著差异(59.4% vs 52.4%,p=0.32)。两组不良事件发生率相当,Charlson合并症指数>2与不良事件风险增加相关。

要点

  • 老年UC患者维多珠单抗持续用药率显著低于非老年患者(51.4% vs 67.6%,p=0.02)。
  • 老年与nonelderly CD患者疗效无显著差异(59.4% vs 52.4%,p=0.32)。
  • Charlson合并症指数>2与不良事件风险增加相关。

核心结论

  • 维多珠单抗可被视为老年IBD患者的安全选择。
  • 其在老年UC患者中的有效性可能降低,而在CD中未观察到年龄依赖的疗效影响。

研究设计与样本

  • LIVE研究为回顾-前瞻性研究,纳入2016年4月至2017年6月起始维多珠单抗的UC和CD患者。
  • 老年患者(≥65岁)按临床1:2匹配非老年患者(18-64岁),随访至停药或2019年6月。
  • 共纳入198例老年患者(108例UC,90例CD)和396例匹配的非老年患者(205例UC,191例CD)。

主要发现

  • 非老年UC患者维多珠单抗持续用药率显著高于老年患者(67.6% vs 51.4%,p=0.02)。
  • 老年与非老年CD患者疗效无显著差异(59.4% vs 52.4%,p=0.32)。
  • 年龄≥65岁与UC中较低的持续用药率相关;CD中既往暴露于抗TNF-α药物、Charlson合并症指数>2及基线中重度临床活动与较低的持续用药率相关。
  • 共记录130例不良事件,两组发生率相当;Charlson合并症指数>2与不良事件风险增加相关。

临床怎么用

  • 原文结论指出维多珠单抗可被视为老年IBD患者的安全选择,其在老年UC患者中的有效性可能降低,而CD中未观察到年龄依赖的疗效影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), but few real-life data have been reported in this population. AIMS: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. METHODS: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18-64 years); the 2 groups were followed until drug discontinuation or June 2019. RESULTS: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p = 0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p = 0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. CONCLUSION: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pugliese D, Privitera G, Crispino F, et al. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022. PMID: 35876062. doi:10.1111/apt.16923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。